Search

Your search keyword '"Walsh, T.J."' showing total 5 results
Start Over Author "Walsh, T.J." Topic infectious diseases
5 results on '"Walsh, T.J."'

1. Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium

Author

George Richard Thompson, David R. Andes, Luis Ostrosky-Zeichner, John R. Perfect, Elizabeth Dodds Ashley, Melissa D. Johnson, Oliver A. Cornely, Russell E. Lewis, Peter G. Pappas, Theoklis E. Zaoutis, Thomas J. Walsh, Dimitrios P. Kontoyiannis, Johnson M.D., Lewis R.E., Dodds Ashley E.S., Ostrosky-Zeichner L., Zaoutis T., Thompson G.R., Andes D.R., Walsh T.J., Pappas P.G., Cornely O.A., Perfect J.R., and Kontoyiannis D.P.

Subjects
0301 basic medicine, Antifungal Agents, Psychological intervention, Drug Resistance, diagnostic, Inappropriate Prescribing, Medical and Health Sciences, antifungal, aspergillosis, candidiasis, diagnostics, guidelines, stewardship, Antimicrobial Stewardship, 0302 clinical medicine, Immunology and Allergy, Antimicrobial stewardship, aspergillosi, 030212 general & internal medicine, Evidence-Based Medicine, Biological Sciences, Infectious Diseases, Fungal, Practice Guidelines as Topic, Engineering ethics, Supplement Article, Clinical Competence, Drug Monitoring, Infection, guideline, Antifungal, medicine.medical_specialty, medicine.drug_class, Best practice, 030106 microbiology, candidiasi, Drug Prescriptions, Microbiology, Vaccine Related, 03 medical and health sciences, Clinical Research, medicine, Humans, Complex field, Public health, Group education, Quality Education, Emerging Infectious Diseases, Mycoses, Stewardship, Business
Abstract

In recent years, the global public health community has increasingly recognized the importance of antimicrobial stewardship (AMS) in the fight to improve outcomes, decrease costs, and curb increases in antimicrobial resistance around the world. However, the subject of antifungal stewardship (AFS) has received less attention. While the principles of AMS guidelines likely apply to stewarding of antifungal agents, there are additional considerations unique to AFS and the complex field of fungal infections that require specific recommendations. In this article, we review the literature on AMS best practices and discuss AFS through the lens of the global core elements of AMS. We offer recommendations for best practices in AFS based on a synthesis of this evidence by an interdisciplinary expert panel of members of the Mycoses Study Group Education and Research Consortium. We also discuss research directions in this rapidly evolving field. AFS is an emerging and important component of AMS, yet requires special considerations in certain areas such as expertise, education, interventions to optimize utilization, therapeutic drug monitoring, and data analysis and reporting.

Published
2020

2. Pharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections

Author

Thomas J. Walsh, Russell E. Lewis, Jill Adler-Moore, Walsh T.J., Lewis R.E., and Adler-Moore J.

Subjects
Microbiology (medical), Infectious Diseases, Systemic mycosis, business.industry, fungal infection, LAmB, Medicine, Amphotericin B liposomal, Liposomal amphotericin, Supplement Articles, liposomal amphotericin B, Pharmacology, business
Abstract

nessuna

Published
2019

3. Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B

Author

Jill Adler-Moore, Roger J. M. Brüggemann, Thomas J. Walsh, Bart J. A. Rijnders, Andreas H. Groll, Russell E. Lewis, Groll A.H., Rijnders B.J.A., Walsh T.J., Adler-Moore J., Lewis R.E., Bruggemann R.J.M., and Internal Medicine

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Antifungal Agents, 030106 microbiology, Supplement Articles, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Amphotericin B, pharmacodynamics, medicine, Animals, Humans, liposomal amphotericin B, 030212 general & internal medicine, Clinical efficacy, Intensive care medicine, business.industry, fungal infection, Fungi, clinical trial, Clinical trial, pharmacodynamic, Treatment Outcome, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Infectious Diseases, Clinical research, Tolerability, Pharmacodynamics, Liposomal amphotericin, business, pharmacokinetics, Invasive Fungal Infections, medicine.drug
Abstract

Contains fulltext : 205145.pdf (Publisher’s version ) (Open Access) Since its introduction in the 1990s, liposomal amphotericin B (LAmB) continues to be an important agent for the treatment of invasive fungal diseases caused by a wide variety of yeasts and molds. This liposomal formulation was developed to improve the tolerability of intravenous amphotericin B, while optimizing its clinical efficacy. Since then, numerous clinical studies have been conducted, collecting a comprehensive body of evidence on its efficacy, safety, and tolerability in the preclinical and clinical setting. Nevertheless, insights into the pharmacokinetics and pharmacodynamics of LAmB continue to evolve and can be utilized to develop strategies that optimize efficacy while maintaining the compound's safety. In this article, we review the clinical pharmacokinetics, pharmacodynamics, safety, and efficacy of LAmB in a wide variety of patient populations and in different indications, and provide an assessment of areas with a need for further clinical research.

Published
2019

4. Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B

Author

Bart J. A. Rijnders, Andreas H. Groll, Jill Adler-Moore, Roger J. M. Brüggemann, Thomas J. Walsh, Russell E. Lewis, Medical Microbiology & Infectious Diseases, Adler-Moore J., Lewis R.E., Bruggemann R.J.M., Rijnders B.J.A., Groll A.H., and Walsh T.J.

Subjects
0301 basic medicine, Microbiology (medical), Antifungal Agents, 030106 microbiology, LAmB, Supplement Articles, Spleen, Microbial Sensitivity Tests, Pharmacology, Kidney, 03 medical and health sciences, Minimum inhibitory concentration, 0302 clinical medicine, Pharmacokinetics, Amphotericin B, Amphotericin B deoxycholate, pharmacodynamics, medicine, preclinical, Animals, Humans, 030212 general & internal medicine, liposomal amphotericin B, pharmacokinetic, Lung, Dose-Response Relationship, Drug, business.industry, Fungi, pharmacodynamic, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Infectious Diseases, medicine.anatomical_structure, Liver, Pharmacodynamics, business, pharmacokinetics, Invasive Fungal Infections, medicine.drug
Abstract

Contains fulltext : 205184.pdf (Publisher’s version ) (Open Access) The improved safety profile and antifungal efficacy of liposomal amphotericin B (LAmB) compared to conventional amphotericin B deoxycholate (DAmB) is due to several factors including, its chemical composition, rigorous manufacturing standards, and ability to target and transit through the fungal cell wall. Numerous preclinical studies have shown that LAmB administered intravenously distributes to tissues frequently infected by fungi at levels above the minimum inhibitory concentration (MIC) for many fungi. These concentrations can be maintained from one day to a few weeks, depending upon the tissue. Tissue accumulation is dose-dependent with drug clearance occurring most rapidly from the brain and slowest from the liver and spleen. LAmB localizes in lung epithelial lining fluid, within liver and splenic macrophages and in kidney distal tubules. LAmB has been used successfully in therapeutic and prophylactic animal models to treat many different fungal pathogens, significantly increasing survival and reducing tissue fungal burden.

Published
2019
Full Text
View/download PDF

5. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

Author

Oliver A. Cornely, Joseph Meletiadis, Joerg J. Vehreschild, Abdullah M. S. Al-Hatmi, Martin Hoenigl, Ban Hock Tan, Malcolm Richardson, Alexandro Bonifaz, Zdenek Racil, Monica A. Slavin, Henrik Jeldtoft Jensen, Janos Sinko, Arunaloke Chakrabarti, Dora E. Corzo-Leon, Souha S. Kanj, Alessandro C. Pasqualotto, Rita O. Oladele, Arnaldo Lopes Colombo, William J. Steinbach, Ronen Ben-Ami, Livio Pagano, Ashraf S. Ibrahim, Georg Maschmeyer, Jacques F. Meis, Zoi D. Pana, Neeraj Sidharthan, Methee Chayakulkeeree, Atul Patel, Nina Singh, Seyedmojtaba Seyedmousavi, Sharon C.-A. Chen, Brad Spellberg, Dong-Gun Lee, Maria J G T Vehreschild, Frédéric Lamoth, Andreas H. Groll, Sevtap Arikan-Akdagli, Marcio Nucci, Andrew J. Ullmann, Katrien Lagrou, Rajeev Soman, Danila Seidel, Thomas J. Walsh, Roger Wahba, Nikolay Klimko, Fanny Lanternier, Badre E. Lmimouni, Sibylle C. Mellinghoff, P. Lewis White, Stéphane Bretagne, Murat Akova, Emmanuel Roilides, Ana Alastruey-Izquierdo, Alexandre Alanio, Cornelia Lass-Floerl, Markus Ruhnke, Anna Skiada, Mihai Mares, Eric Dannaoui, Mervyn Mer, Hamid Badali, Bruno Hochhegger, Thomas Lehrnbecher, Dorothee Arenz, C. Orla Morrissey, Elio Castagnola, Jesús Guinea, Lubos Drgona, Russell E. Lewis, Nathan P. Wiederhold, Michaela Lackner, Claus Peter Heussel, Theoklis E. Zaoutis, Donald C. Sheppard, University Hospital of Cologne [Cologne], Instituto de Salud Carlos III [Madrid] (ISC), The University of Sydney, Unité de Parasitologie-Mycologie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Paris Cité (UPCité), University of California [San Diego] (UC San Diego), University of California (UC), Medical University Graz, University Hospitals Leuven [Leuven], University of the Witwatersrand [Johannesburg] (WITS), Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases - CECAD [Cologne, Germany] (Institute for Genetics), University of Cologne, German Centre for Infection Research (DZIF), McGill University = Université McGill [Montréal, Canada], Hacettepe University School of Medicine, Mycologie moléculaire - Molecular Mycology, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7), Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals (CNRMA), Institut Pasteur [Paris] (IP), Radboud University Medical Center [Nijmegen], Ankara University School of Medicine [Turkey], Department of Infectious Diseases and Tropical Medicine [Paris], Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5), Medical Microbiology & Infectious Diseases, Cornely O.A., Alastruey-Izquierdo A., Arenz D., Chen S.C.A., Dannaoui E., Hochhegger B., Hoenigl M., Jensen H.E., Lagrou K., Lewis R.E., Mellinghoff S.C., Mer M., Pana Z.D., Seidel D., Sheppard D.C., Wahba R., Akova M., Alanio A., Al-Hatmi A.M.S., Arikan-Akdagli S., Badali H., Ben-Ami R., Bonifaz A., Bretagne S., Castagnola E., Chayakulkeeree M., Colombo A.L., Corzo-Leon D.E., Drgona L., Groll A.H., Guinea J., Heussel C.-P., Ibrahim A.S., Kanj S.S., Klimko N., Lackner M., Lamoth F., Lanternier F., Lass-Floerl C., Lee D.-G., Lehrnbecher T., Lmimouni B.E., Mares M., Maschmeyer G., Meis J.F., Meletiadis J., Morrissey C.O., Nucci M., Oladele R., Pagano L., Pasqualotto A., Patel A., Racil Z., Richardson M., Roilides E., Ruhnke M., Seyedmousavi S., Sidharthan N., Singh N., Sinko J., Skiada A., Slavin M., Soman R., Spellberg B., Steinbach W., Tan B.H., Ullmann A.J., Vehreschild J.J., Vehreschild M.J.G.T., Walsh T.J., White P.L., Wiederhold N.P., Zaoutis T., and Chakrabarti A.

Subjects
0301 basic medicine, medicine.medical_specialty, Posaconazole, [SDV]Life Sciences [q-bio], 030106 microbiology, MEDLINE, Disease, mucormycosis, guideline, diagnosis, treatment, mucormycosis, Article, 03 medical and health sciences, 0302 clinical medicine, Amphotericin B deoxycholate, Medicine, Humans, 030212 general & internal medicine, Disease management (health), Intensive care medicine, business.industry, Mucormycosis, Disease Management, Guideline, medicine.disease, Settore MED/15 - MALATTIE DEL SANGUE, Infectious Diseases, business, medicine.drug, Rare disease
Abstract

BackgroundMucormycosis is a difficult to diagnose rare disease with high morbidity and mortality. Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and medical intervention is lifesaving. Guidance on the complex multidisciplinary management has potential to improve prognosis, but approaches differ between health care settings.MethodsFrom January 2018, authors from 33 countries in all United Nations regions analysed the published evidence on mucormycosis management and provided consensus recommendations addressing differences between the regions of the world as part of the “One World One Guideline” initiative of the European Confederation of Medical Mycology (ECMM). The author group based in 17 time zones, relied on electronic media including video tutorial on methodology, and central document repository with several daily updates.FindingsSigns and symptoms of mucormycosis depend on organ patterns and underlying conditions. Diagnostic management does not differ greatly between world regions. Upon suspicion of mucormycosis appropriate imaging is strongly recommended to document extent of disease and is followed by strongly recommended surgical intervention. First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous isavuconazole and intravenous or delayed release tablet posaconazole are recommended with moderate strength. Both triazoles are strongly recommended salvage treatments. Amphotericin B deoxycholate is recommended against, because of substantial toxicity, but may be the only option in resource limited settings.InterpretationManagement of mucormycosis depends on recognising disease patterns and on early diagnosis. Limited availability of contemporary treatments burdens patients in low and middle income settings. Areas of uncertainty were identified and future research directions specified.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results